Molecular Partners

A bad day for Molecular Partners
EP Vantage
Wed, 04/27/22 - 10:45 am
Molecular Partners
MP0310
Amgen
Novartis
ensovibep
Novartis snaps up the rights to a Covid-19 antiviral after seeing mid-stage results. So where are the data?
Endpoints
Mon, 01/10/22 - 11:31 pm
Novartis
Molecular Partners
clinical trials
COVID-19
antivirals
ensovibep
Molecular Partners' Covid-19 therapy proves inactiv
EP Vantage
Tue, 11/16/21 - 11:54 am
Molecular Partners
COVID-19
clinical trials
NIH
AbbVie hands back headline drug in $63B Allergan buyout to Molecular Partners after FDA rejection. What's next?
Endpoints
Mon, 08/9/21 - 11:54 pm
AbbVie
Allergan
Molecular Partners
Another four IPOs complete busy week as biotech raise continues to match 2020's record pace
Endpoints
Fri, 06/18/21 - 10:06 am
IPOs
Lyell Immunopharma
Verve Therapeutics
Molecular Partners
ATAI Life Sciences
Century Therapeutics
Ambrx
Cyteir Therapeutics
Molecular Partners prices $64M IPO, falling short of original goal
Fierce Biotech
Wed, 06/16/21 - 11:49 am
Molecular Partners
IPOs
Novartis, Molecular Partners launch trial to test ensovibep as COVID treatment
Biopharma Reporter
Thu, 06/3/21 - 12:11 am
Novartis
Molecular Partners
ensovibep
COVID-19
clinical trials
Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies
BioSpace
Sun, 04/25/21 - 01:47 pm
Molecular Partners
IPOs
Novartis taps Molecular Partners for a new way to defeat COVID-19
Fierce Biotech
Wed, 10/28/20 - 10:33 am
Novartis
Molecular Partners
antivirals
MP0420
MP0423
COVID-19
FDA rejects AbbVie's eye drug, citing safety concerns
BioPharma Dive
Fri, 06/26/20 - 01:00 pm
Allergan
AbbVie
FDA
abicipar
Molecular Partners
wet age-related macular degeneration
Does an improved safety profile strengthen Allergan's case for a wet AMD challenge to Lucentis?
Endpoints
Tue, 04/2/19 - 12:04 pm
Allergan
abicipar
wet age-related macular degeneration
Lucentis
Molecular Partners
Amgen pays $50M for Molecular Partners’ preclinical bispecific
Fierce Biotech
Wed, 12/19/18 - 10:07 am
Amgen
Molecular Partners
MP0310
Roche backs out of its $1B cancer deal with Molecular Partners
Fierce Biotech
Fri, 07/24/15 - 09:08 am
Roche
Molecular Partners
DARPin
R&D
Actavis keeps its Phase III promise with Molecular Partners' eye drug
Fierce Biotech
Mon, 05/11/15 - 09:21 am
Actavis
Molecular Partners
abicipar
wet age-related macular degeneration
Roche teams with Molecular Partners on armed proteins in $1B-plus deal
Fierce Biotech
Wed, 12/4/13 - 10:18 am
Roche
Molecular Partners
DARPin
Allergan adds $1.5B R&D pact as it builds ophthalmology pipeline
Fierce Biotech
Tue, 08/21/12 - 12:07 pm
Allergan
ophthalmology
Molecular Partners
Swiss Biotech IPOs May Revive Industry Starved of Investment
Bloomberg
Thu, 07/7/11 - 10:15 pm
IPOs
Roche
Novartis
Actelion
Molecular Partners
Newron Pharma
Switzerland
Allergan licenses retinal disease treatment from Molecular Partners in $420 million deal
Yahoo/AP
Wed, 05/4/11 - 08:45 pm
Allergan
Molecular Partners
retinal disease